I saw Chalon Magnuson, the master aesthetician at werschler aesthetics. She was amazing and the coolsculpting was too! I lost 2 pant sizes after 2 max treatments on my abdomen and i didnt change anything else in my daily routine while losing the weight. The coolsculpting did it all and is worth so much more than what i paid. I have done 6 treatments so far and plan on more in the near future!
Because from my friends I had heard he was the best. I traveled over 1,500 miles just to see him.
One of the best doctors in the world.
I left a cancer spot on my cheek untreated for 2 years. The cancer was growing and my cheak was turning white. The skin above the the cancer looked like scars. Dr W had to remove most of my left cheek. Within, a few months, no one could tell I had ever had the surgery, and all of the cancer was gone. I wish you could see the pictures!!
I have very deep lines on my forehead as well as between my eyes. It has worked very well and I'm already planning for my next visit to my dermatologist. I did have some bruising but he did quite alot.. I am also using Differin for acne, brown spots and fine lines..huge improvement!
HORRIBLE! Dr. Werschler did a thread lift that was HORRIBLE! See photos! He refused to refund my money and it took months for the puckering and folds to go away! I would not recommend him to anyone! Apparently, he hasn't done many thread lifts and didn't know what the heck he was doing! Immediately after the procedure, he scurried out of the room leaving his assistant to try to explain to me why my face looked the way it did. I had done my research on thread lifts and watched many videos and absolutely NONE of the after photos looked like mine!
We recently announced interim results from a long-term safety and patient satisfaction study on Artefill, the first and only FDA-approved microsphere-enhanced dermal filler for the correction of smile lines. Our initial analysis is very encouraging as it further validates Artefill’s strong safety profile and high level of patient satisfaction for long-term wrinkle correction. A granuloma incidence rate of less than 0.1% is also indicative of this and suggests Artefill is as safe as other dermal fillers, such as Juvederm and Restylane. FOR IMMEDIATE RELEASE Suneva Medical Announces Positive Interim Data from Five-Year Safety and Patient Satisfaction Study on Artefill® Study Suggests Artefill Is As Safe as Other Dermal Fillers for Nasolabial Fold Correction Data Presented at Maui Derm 2010 Meeting MAUI, HAWAII -- January 25, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler. The data is being presented by study investigator W. Philip Werschler, M.D., FAAD, FAACS, Assistant Clinical Professor in Medicine/Dermatology at University of Washington, at the Advances in Cosmetic and Medical Dermatology’s “Maui Derm 2010” Meeting taking place in Maui, Hawaii January 23-27th. Dr. Werschler commented, “Our initial analysis is very encouraging as it further validates Artefill’s strong safety profile and high level of patient satisfaction for long-term wrinkle correction. A granuloma incidence rate of less than 0.1% is also indicative of this and suggests Artefill is as safe as other dermal fillers, such as Juvederm and Restylane.” The 23-center, prospective, open-label study consists of 1,008 patients who had no recent history of nasolabial fold correction. Patients received an initial treatment with Artefill, and up to two touch-ups after 30 and 60 days, until full correction was achieved. Potential adverse events and satisfaction data are reported by all patients at 2, 6, 12, 18, 24, 36, 48 and 60 months to assess the presence of or absence of adverse events, patient satisfaction, and any changes in health. Potential subject-reported AEs were followed up by phone (non-device related) and/or office visit and possible granulomas were analyzed by biopsy. All study patients will complete a final in-office visit at 60-months. Niv Caviar, President and Chief Executive Officer of Suneva Medical commented, “These results are consistent with what we observed during the pivotal trial and further validate Artefill’s role as a long-lasting filler in the aesthetic market. We look forward to reporting additional interim results later this year as more patients reach the two-year point.” About ArtefillArtefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. Since Artefill was approved in 2006, over 20,000 patients have been treated successfully with very high satisfaction rates. For more information visit www.artefill.com <http://www.artefill.com> . About Suneva Medical Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company’s lead product is Artefill®, the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines. For more information visit www.sunevamedical.com
